Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 33
Filter
1.
JAMA ; 326(11): 1007-1008, 2021 Sep 21.
Article in English | MEDLINE | ID: covidwho-1439647
3.
Nat Rev Nephrol ; 17(8): 554-568, 2021 08.
Article in English | MEDLINE | ID: covidwho-1319029

ABSTRACT

Although overall donation and transplantation activity is higher in Europe than on other continents, differences between European countries in almost every aspect of transplantation activity (for example, in the number of transplantations, the number of people with a functioning graft, in rates of living versus deceased donation, and in the use of expanded criteria donors) suggest that there is ample room for improvement. Herein we review the policy and clinical measures that should be considered to increase access to transplantation and improve post-transplantation outcomes. This Roadmap, generated by a group of major European stakeholders collaborating within a Thematic Network, presents an outline of the challenges to increasing transplantation rates and proposes 12 key areas along with specific measures that should be considered to promote transplantation. This framework can be adopted by countries and institutions that are interested in advancing transplantation, both within and outside the European Union. Within this framework, a priority ranking of initiatives is suggested that could serve as the basis for a new European Union Action Plan on Organ Donation and Transplantation.


Subject(s)
Organ Transplantation , Tissue and Organ Procurement , Europe/epidemiology , European Union , Humans , Kidney Transplantation/statistics & numerical data , Organ Transplantation/statistics & numerical data , Stakeholder Participation , Tissue and Organ Procurement/organization & administration , Tissue and Organ Procurement/statistics & numerical data , Waiting Lists/mortality
5.
Clin Anat ; 34(6): 961-965, 2021 Sep.
Article in English | MEDLINE | ID: covidwho-1242706

ABSTRACT

The inclusion of human body dissection in anatomical science curricula has been described as a critical educational experience for the mastery of anatomical structures and concepts. To ensure that body donors are ethically acquired and suitable for anatomy education, Anatomical Donation Programs (ADPs) are tasked with the responsibility of acquiring body donors for basic and clinical science curricula. Considering the personal and institutional impact of SARS-CoV-2, a national survey was conducted to examine the current effect of the pandemic on ADP protocols, body donation, and the sustainability of ADPs in the United States (U.S.). Eighty-nine U.S. ADPs were identified and contacted for optional participation in a survey to assess the impact of the SARS-CoV-2 pandemic on their programs. Survey data were collected and managed using REDCap electronic data capture tools. Thirty-six ADPs (40.5% response rate) from the nine U.S. Divisions are represented in the survey results. Data were collected on ADP descriptions and demographics, SARS-CoV-2 impact on ADPs and protocols, and body donation and ADP sustainability. Almost all ADPs reported that the pandemic has affected their ADP operations in some way; however, the sustainability for the majority of ADPs appears likely and donor availability remains stable due to a proportional decrease in body donations and body donor requests. As the long-term impact on ADPs has yet to be determined, the authors plan to reevaluate the lasting impact of the SARS-CoV-2 pandemic on body donation, ADP sustainability, and anatomical science education throughout the year 2021.


Subject(s)
Anatomy/education , COVID-19/prevention & control , Cadaver , Education, Medical , Tissue and Organ Procurement/organization & administration , COVID-19/epidemiology , COVID-19/transmission , Curriculum , Humans , United States
6.
Ann Transplant ; 26: e929946, 2021 Apr 23.
Article in English | MEDLINE | ID: covidwho-1200360

ABSTRACT

BACKGROUND This single-center study analyzed distinctions between lung transplants performed in the Department of Cardiac and Vascular surgery of the University Clinical Center in Gdansk, Poland before and during the COVID-19 pandemic. MATERIAL AND METHODS There were 189 patients who underwent the qualification procedure to lung transplantation in the Department of Cardiac and Vascular Surgery of the University Clinical Center in Gdansk, Poland in the years 2019 and 2020. The control group consisted of 12 patients transplanted in 2019, and the study group consisted of 16 patients transplanted in 2020. RESULTS During 2019, the qualification process was performed in 102 patients with pulmonary end-stage diseases. In 2020, despite the 3-month lockdown related to organizational changes in the hospital, 87 qualification processes were performed. The mortality rate of patients on the waiting list in 2020 was 14.3% (6 patients died), and during 2019 the rate was also 14.3% (4 patients died). Donor qualifications were according to ISHLT criteria. The distribution of donors in both years was similar. There was no relationship between the geographic area of residence and source of donors. In 2019, all 12 patients had double-lung transplant. In 2020, 11 patients had double-lung transplant and 5 patients had single-lung transplant. There was no difference in ventilation time and PGD aside from a shorter ICU stay in 2020. CONCLUSIONS Lung transplants were relatively well-conducted despite the continued obstacles of the COVID-19 pandemic.


Subject(s)
COVID-19 , Health Services Accessibility/trends , Lung Transplantation/trends , Tissue and Organ Procurement/trends , Waiting Lists/mortality , Adult , Aged , COVID-19/epidemiology , COVID-19/prevention & control , Female , Follow-Up Studies , Health Services Accessibility/organization & administration , Humans , Lung Transplantation/mortality , Male , Middle Aged , Outcome and Process Assessment, Health Care , Pandemics , Poland/epidemiology , Tissue and Organ Procurement/organization & administration
9.
Prog Transplant ; 31(2): 171-173, 2021 06.
Article in English | MEDLINE | ID: covidwho-1136201

ABSTRACT

The COVID-19 pandemic has been well-documented to have a variable impact on individual communities and health care systems. We describe the experience of a single organ procurement organization (OPO), located in an area without a large cluster of cases during the initial phase of the COVID-19 pandemic. A review of community health data describing the impact of COVID-19 nationally and in Oklahoma was conducted. Additionally, a retrospective review of available OPO data from March 2019-May 2020 was performed. While the amount of donor referrals received and organs recovered by the OPO remained stable in the initial months of the pandemic, the observed organs transplanted vs. expected organs transplanted (O:E) decreased to the lowest number in the 15-month period and organs transplanted decreased as well. Fewer organs from Oklahoma donors were accepted for transplant despite staff spending more time allocating organs.


Subject(s)
COVID-19 , Organ Transplantation/statistics & numerical data , Tissue Donors/supply & distribution , Tissue Donors/statistics & numerical data , Tissue and Organ Procurement/organization & administration , Tissue and Organ Procurement/statistics & numerical data , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Oklahoma/epidemiology , Pandemics , Retrospective Studies , SARS-CoV-2 , United States/epidemiology
10.
Transpl Int ; 34(4): 612-621, 2021 04.
Article in English | MEDLINE | ID: covidwho-1066771

ABSTRACT

The COVID-19 pandemic has significantly changed the landscape of kidney transplantation in the United States and worldwide. In addition to adversely impacting allograft and patient survival in postkidney transplant recipients, the current pandemic has affected all aspects of transplant care, including transplant referrals and listing, organ donation rates, organ procurement and shipping, and waitlist mortality. Critical decisions were made during this period by transplant centers and individual transplant physicians taking into consideration patient safety and resource utilization. As countries have begun administering the COVID vaccines, new and important considerations pertinent to our transplant population have arisen. This comprehensive review focuses on the impact of COVID-19 on kidney transplantation rates, mortality, policy decisions, and the clinical management of transplanted patients infected with COVID-19.


Subject(s)
COVID-19 , Health Policy , Kidney Failure, Chronic/surgery , Kidney Transplantation/trends , Perioperative Care/trends , Tissue and Organ Procurement/trends , Waiting Lists/mortality , COVID-19/complications , COVID-19/diagnosis , COVID-19/epidemiology , COVID-19/prevention & control , COVID-19 Vaccines , Europe/epidemiology , Health Care Rationing , Health Services Accessibility/trends , Humans , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/mortality , Kidney Transplantation/methods , Kidney Transplantation/mortality , Pandemics , Perioperative Care/methods , Tissue and Organ Procurement/methods , Tissue and Organ Procurement/organization & administration , United States/epidemiology
11.
J Thorac Cardiovasc Surg ; 163(1): 326-335.e6, 2022 01.
Article in English | MEDLINE | ID: covidwho-1036418

ABSTRACT

OBJECTIVES: The study objectives were to illustrate our workflow for lung donation and transplantation during the Coronavirus Disease 2019 crisis and to report our preliminary experience with perioperative care. METHODS: We retrospectively analyzed data in the China Lung Transplantation Registration from January 23, 2020, to March 23, 2020 (2020 cohort), compared with the same period in 2019 (2019 cohort). Pre- and post-lung transplantation management strategies, including measures aiming to prevent severe acute respiratory syndrome coronavirus 2 infection, were applied to all recipients, including 5 post-Coronavirus Disease 2019 transplants during the Coronavirus Disease 2019 pandemic period in China. RESULTS: Twenty-eight lung transplant procedures were performed, including lung transplant for 5 patients with acute respiratory distress syndrome due to Coronavirus Disease 2019-related pulmonary fibrosis. Compared with the 2019 cohort, more patients with urgent conditions received transplantation in 2020, with a shorter pre-lung transplant admission time and early mobilization post-lung transplant. A large proportion (60%) of lung donations were transported on high-speed trains and commercial flights or highways and commercial flights. Grafts in the preservation containers were handed over to the receiving staff at the airport for 40% (10/25) of donations, which reduced the unnecessary quarantine of transporting staff entering the city. Listed candidates were urgently transferred to other qualified centers in 17.9% of cases (5/28), which reduced the risk of severe acute respiratory syndrome coronavirus 2 exposure in Coronavirus Disease 2019-designated hospitals. The 90-day survival of the transplant recipients in 2020 was 85.7%, including 3 of 5 recipients (60%) who had critically severe Coronavirus Disease 2019. CONCLUSIONS: Lung transplant and donation amid Coronavirus Disease 2019 can be performed safely with coordinated efforts on medical resource sharing and medical staff protection based on stratification of the infection risk. Outcomes were not compromised during the Coronavirus Disease 2019 outbreak. Lung transplantion can be regarded as salvage therapy for critical patients with Coronavirus Disease 2019 with a confirmed positive turned negative virology status.


Subject(s)
COVID-19 , Lung Transplantation/statistics & numerical data , Adult , China/epidemiology , Female , Humans , Length of Stay/statistics & numerical data , Male , Middle Aged , Pandemics , Respiratory Distress Syndrome/surgery , Respiratory Distress Syndrome/virology , Retrospective Studies , Tissue and Organ Procurement/organization & administration
12.
Am J Clin Pathol ; 155(4): 515-521, 2021 Mar 15.
Article in English | MEDLINE | ID: covidwho-1007437

ABSTRACT

OBJECTIVES: Serologic testing for antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in potential donors of coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) may not be performed until after blood donation. A hospital-based recruitment program for CCP may be an efficient way to identify potential donors prospectively. METHODS: Patients who recovered from known or suspected COVID-19 were identified and recruited through medical record searches and public appeals in March and April 2020. Participants were screened with a modified donor history questionnaire and, if eligible, were asked for consent and tested for SARS-CoV-2 antibodies (IgG and IgM). Participants positive for SARS-CoV-2 IgG were referred for CCP collection. RESULTS: Of 179 patients screened, 128 completed serologic testing and 89 were referred for CCP donation. IgG antibodies to SARS-CoV-2 were detected in 23 of 51 participants with suspected COVID-19 and 66 of 77 participants with self-reported COVID-19 confirmed by polymerase chain reaction (PCR). The anti-SARS-CoV-2 IgG level met the US Food and Drug Administration criteria for "high-titer" CCP in 39% of participants confirmed by PCR, as measured by the Ortho VITROS IgG assay. A wide range of SARS-CoV-2 IgG levels were observed. CONCLUSIONS: A hospital-based CCP donor recruitment program can prospectively identify potential CCP donors. Variability in SARS-CoV-2 IgG levels has implications for the selection of CCP units for transfusion.


Subject(s)
COVID-19 Serological Testing/methods , COVID-19/therapy , Tissue and Organ Procurement/methods , Adolescent , Adult , Aged , Aged, 80 and over , Female , Hospitals , Humans , Immunization, Passive , Linear Models , Male , Middle Aged , San Francisco , Tissue Donors , Tissue and Organ Procurement/organization & administration , Young Adult , COVID-19 Serotherapy
17.
Clin Transplant ; 34(12): e14086, 2020 12.
Article in English | MEDLINE | ID: covidwho-751771

ABSTRACT

In our first survey of transplant centers in March 2020, >75% of kidney and liver programs were either suspended or operating under restrictions. To safely resume transplantation, we must understand the evolving impact of COVID-19 on transplant recipients and center-level practices. We therefore conducted a six-week follow-up survey May 7-15, 2020, and linked responses to the COVID-19 incidence map, with a response rate of 84%. Suspension of live donor transplantation decreased from 72% in March to 30% in May for kidneys and from 68% to 52% for livers. Restrictions/suspension of deceased donor transplantation decreased from 84% to 58% for kidneys and from 73% to 42% for livers. Resuming transplantation at normal capacity was envisioned by 83% of programs by August 2020. Exclusively using local recovery teams for deceased donor procurement was reported by 28%. Respondents reported caring for a total of 1166 COVID-19-positive transplant recipients; 25% were critically ill. Telemedicine challenges were reported by 81%. There was a lack of consensus regarding management of potential living donors or candidates with SARS-CoV-2. Our findings demonstrate persistent heterogeneity in center-level response to COVID-19 even as transplant activity resumes, making ongoing national data collection and real-time analysis critical to inform best practices.


Subject(s)
COVID-19/prevention & control , Health Services Accessibility/trends , Organ Transplantation/trends , Organizational Policy , Practice Patterns, Physicians'/trends , Telemedicine/trends , Tissue and Organ Procurement/trends , Adult , COVID-19/diagnosis , COVID-19/epidemiology , COVID-19/etiology , COVID-19 Testing , Clinical Decision-Making , Follow-Up Studies , Health Care Surveys , Health Services Accessibility/organization & administration , Humans , Incidence , Infection Control/methods , Infection Control/trends , Organ Transplantation/methods , Postoperative Complications/epidemiology , Postoperative Complications/prevention & control , Postoperative Complications/virology , Tissue and Organ Procurement/organization & administration , United States/epidemiology
18.
Am J Transplant ; 20(11): 3123-3130, 2020 11.
Article in English | MEDLINE | ID: covidwho-733265

ABSTRACT

Many deceased-donor and living-donor kidney transplants (KTs) rely on commercial airlines for transport. However, the coronavirus-19 pandemic has drastically impacted the commercial airline industry. To understand potential pandemic-related disruptions in the transportation network of kidneys across the United States, we used national flight data to compare scheduled flights during the pandemic vs 1-year earlier, focusing on Organ Procurement Organization (OPO) pairs between which kidneys historically most likely traveled by direct flight (High Volume by direct Air transport OPO Pairs, HVA-OPs). Across the United States, there were 39% fewer flights in April 2020 vs April 2019. Specific to the kidney transportation network, there were 65.1% fewer flights between HVA-OPs, with considerable OPO-level variation (interquartile range [IQR] 54.7%-75.3%; range 0%-100%). This translated to a drop in median number of flights between HVA-OPs from 112 flights/wk in April 2019 to 34 in April 2020 (P < .001), and a rise in wait time between scheduled flights from 1.5 hours in April 2019 (IQR 0.76-3.3) to 4.9 hours in April 2020 (IQR 2.6-11.2; P < .001). Fewer flights and longer wait times can impact logistics as well as cold ischemia time; our findings motivate an exploration of creative approaches to KT transport as the impact of this pandemic on the airline industry evolves.


Subject(s)
Aircraft/statistics & numerical data , COVID-19/epidemiology , Kidney Transplantation/methods , Pandemics , Renal Insufficiency/surgery , Tissue Donors/supply & distribution , Tissue and Organ Procurement/organization & administration , Comorbidity , Female , Humans , Male , Renal Insufficiency/epidemiology , Retrospective Studies , SARS-CoV-2 , United States/epidemiology
19.
J Hepatol ; 73(4): 873-881, 2020 10.
Article in English | MEDLINE | ID: covidwho-701738

ABSTRACT

BACKGROUND & AIMS: The outbreak of COVID-19 has vastly increased the operational burden on healthcare systems worldwide. For patients with end-stage liver failure, liver transplantation is the only option. However, the strain on intensive care facilities caused by the pandemic is a major concern. There is an urgent need for ethical frameworks to balance the need for liver transplantation against the availability of national resources. METHODS: We performed an international multicenter study of transplant centers to understand the evolution of policies for transplant prioritization in response to the pandemic in March 2020. To describe the ethical tension arising in this setting, we propose a novel ethical framework, the quadripartite equipoise (QE) score, that is applicable to liver transplantation in the context of limited national resources. RESULTS: Seventeen large- and medium-sized liver transplant centers from 12 countries across 4 continents participated. Ten centers opted to limit transplant activity in response to the pandemic, favoring a "sickest-first" approach. Conversely, some larger centers opted to continue routine transplant activity in order to balance waiting list mortality. To model these and other ethical tensions, we computed a QE score using 4 factors - recipient outcome, donor/graft safety, waiting list mortality and healthcare resources - for 7 countries. The fluctuation of the QE score over time accurately reflects the dynamic changes in the ethical tensions surrounding transplant activity in a pandemic. CONCLUSIONS: This four-dimensional model of quadripartite equipoise addresses the ethical tensions in the current pandemic. It serves as a universally applicable framework to guide regulation of transplant activity in response to the increasing burden on healthcare systems. LAY SUMMARY: There is an urgent need for ethical frameworks to balance the need for liver transplantation against the availability of national resources during the COVID-19 pandemic. We describe a four-dimensional model of quadripartite equipoise that models these ethical tensions and can guide the regulation of transplant activity in response to the increasing burden on healthcare systems.


Subject(s)
Coronavirus Infections/epidemiology , End Stage Liver Disease , Health Resources/trends , Liver Transplantation , Pandemics , Pneumonia, Viral/epidemiology , Tissue and Organ Procurement , Betacoronavirus , COVID-19 , End Stage Liver Disease/mortality , End Stage Liver Disease/surgery , Humans , International Cooperation , Liver Transplantation/ethics , Liver Transplantation/methods , Organizational Innovation , Pandemics/ethics , Pandemics/prevention & control , Patient Selection/ethics , SARS-CoV-2 , Surveys and Questionnaires , Tissue and Organ Procurement/ethics , Tissue and Organ Procurement/organization & administration , Tissue and Organ Procurement/trends , Waiting Lists/mortality
SELECTION OF CITATIONS
SEARCH DETAIL